RxSight, Inc. (RXST) stock

RXSTNasdaqOphthalmic GoodsFiscal year ends December 31

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 10/3074% below fair value

$5.32−0.06 (-1.12%)

Close on Nov 13, 2026Market cap $221.28MP/E –Yield –

RxSight total assets

Total assets on the balance sheet at the end of each period.

RxSight's total assets was $352.70M at Jun 30, 2026. For fiscal 2025 it was $311.81M, down 2.1% from the year before. The highest annual figure on record is $318.56M in fiscal 2024.

Annual total assets

Period	Period end	Value	Change
FY2025	Dec 31, 2025	$311.81M	-2.1%
FY2024	Dec 31, 2024	$318.56M	+74.5%
FY2023	Dec 31, 2023	$182.55M	+21.6%
FY2022	Dec 31, 2022	$150.16M	-22.1%
FY2021	Dec 31, 2021	$192.72M	+91.4%
FY2020	Dec 31, 2020	$100.68M	–

Quarterly total assets

Change is against the same quarter a year earlier.

Period	Period end	Value	Change
Q2 FY2026	Jun 30, 2026	$352.70M	+14.1%
Q1 FY2026	Mar 31, 2026	$303.99M	-2.9%
Q4 FY2025	Dec 31, 2025	$311.81M	-2.1%
Q3 FY2025	Sep 30, 2025	$308.53M	-0.6%
Q2 FY2025	Jun 30, 2025	$309.01M	+1.1%
Q1 FY2025	Mar 31, 2025	$313.04M	+70.9%
Q4 FY2024	Dec 31, 2024	$318.56M	+74.5%
Q3 FY2024	Sep 30, 2024	$310.47M	+70.7%
Q2 FY2024	Jun 30, 2024	$305.50M	+56.5%
Q1 FY2024	Mar 31, 2024	$183.17M	-9.6%
Q4 FY2023	Dec 31, 2023	$182.55M	+21.6%
Q3 FY2023	Sep 30, 2023	$181.85M	+16.8%
Q2 FY2023	Jun 30, 2023	$195.26M	+17.1%
Q1 FY2023	Mar 31, 2023	$202.53M	+14.4%
Q4 FY2022	Dec 31, 2022	$150.16M	-22.1%
Q3 FY2022	Sep 30, 2022	$155.71M	-23.6%
Q2 FY2022	Jun 30, 2022	$166.71M	+75.7%
Q1 FY2022	Mar 31, 2022	$177.06M	+75.9%
Q4 FY2021	Dec 31, 2021	$192.72M	–
Q3 FY2021	Sep 30, 2021	$203.74M	–
Q2 FY2021	Jun 30, 2021	$94.89M	–
Q4 FY2020	Dec 31, 2020	$100.68M	–